Lyell Immunopharma, Inc. LYEL
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -65.01%
- 1 year
- -34.92%
- Market cap
- 263.92M
- Revenue (ttm)
- 63.00K
- EPS (ttm)
- -12.86
- Shares out
- 292.16M
- Forward P/E
- -0.73
- YTD return
- -65.01%
- 1-year return
- -34.92%
- Volume
- 78.06K
- Avg volume
- 151.38K
- Open
- 10.92
- Previous close
- 10.88
- Day's range
- 10.58 – 11.59
- 52-week range
- 7.20 – 45.00
- Beta
- -0.48
- Analysts
- Hold
- Price target
- 1.00 (-90.7%)
2Y -14.61 (-57.52%)
Key statistics
- Enterprise value
- -210.89M
- PEG ratio
- 0.00
- Price / sales
- 2854.84
- Price / book
- 0.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 36.00%
- Free cash flow
- -83.12M
- Total cash
- 440.55M
- Total debt
- 58.58M
- Return on equity
- -33.22%
- Short % of float
- 4.36%
- 50-day average
- 1.01
- 200-day average
- 1.68
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.13.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Oct 30, 2024 | B of A Securities | down | Buy | Underperform |
| Oct 28, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 19, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 27, 2024 | B of A Securities | main | Buy | Buy |
| Jun 27, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lyell.com
News
Your note
Sign in to keep a note on LYEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HILL STEPHEN J | Chief Operating Officer | Stock Award(Grant) | Feb 8, 2024 | 48,928 |
| KLAUSNER RICHARD | Director | Sale | Aug 14, 2023 | 0 |
| LANG MATTHEW | Officer | Stock Award(Grant) | Feb 8, 2024 | 50,000 |
| LEE GARY K | Officer | Stock Award(Grant) | Feb 8, 2024 | 52,700 |
| NEWTON CHARLES W. | Chief Financial Officer | Stock Award(Grant) | Feb 8, 2024 | 48,729 |
| SEELY LYNN | Chief Executive Officer | Stock Award(Grant) | Feb 8, 2024 | 200,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MWG Management Ltd | 6.90% | 20,162,332 | 12.41M | Sep 29, 2024 |
| Orland Properties Ltd. | 5.17% | 15,093,969 | 9.29M | Sep 29, 2024 |
| Blackrock Inc. | 4.71% | 13,747,084 | 8.46M | Sep 29, 2024 |
| Vanguard Group Inc | 3.45% | 10,071,482 | 6.20M | Sep 29, 2024 |
| Foresite Capital Management IV, LLC | 2.85% | 8,325,000 | 5.12M | Sep 29, 2024 |
| Wuxi Apptec Co., Ltd. | 2.53% | 7,390,710 | 4.55M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.99% | 5,817,818 | 3.58M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 1.85% | 5,398,783 | 3.32M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.47% | 4,286,388 | 2.64M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.86% | 2,522,865 | 1.55M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.56% | 1,645,833 | 1.01M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.53% | 1,551,919 | 955.36K | Oct 30, 2024 |